New independent director joins WORK Medical Technology Group (WOK) board

Rhea-AI Filing Summary

WORK Medical Technology Group LTD reports a change in its board of directors. On March 23, 2026, independent director Xiaoyang Li resigned from the Board, the Audit, Compensation, and Nominating and Corporate Governance Committees, and as chairperson of the Compensation Committee, citing personal reasons.

To fill this vacancy, the Board appointed Dr. Qisheng Lin as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective the same day. Dr. Lin is a nephrology specialist and academic with roles at Renji Hospital and prior research experience at the Icahn School of Medicine at Mount Sinai. The Board determined he meets the Nasdaq “independent director” standard. This report is incorporated by reference into the Company’s Form F-3 registration statement (File No. 333-289943).

Key Figures

Effective date of resignation and appointment: March 23, 2026 Form F-3 file number: 333-289943 Company phone number: +86-571-82613568 +1 more

4 metrics

Effective date of resignation and appointment March 23, 2026 Board and committee changes became effective on this date

Form F-3 file number 333-289943 Registration statement into which this report is incorporated

Company phone number +86-571-82613568 Contact for WORK Medical Technology Group’s principal executive office

Report signature date April 15, 2026 Date the report was signed by the Chief Executive Officer

Key Terms

independent director, Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee, +2 more

6 terms

independent director financial

"Mr. Xiaoyang Li, an independent director of WORK Medical Technology Group LTD"

An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.

Audit Committee financial

"resigned from the board of directors and as a member of the Audit Committee"

A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.

Compensation Committee financial

"and as the chairperson of the Compensation Committee of the Board"

A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.

Nominating and Corporate Governance Committee financial

"a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee"

A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.

Nasdaq Listing Rule 5605(a)(2) financial

"The Board has determined that Dr. Lin is an “independent director” as defined under Nasdaq Listing Rule 5605(a)(2)."

Nasdaq Listing Rule 5605(a)(2) sets the criteria Nasdaq uses to decide whether a company’s board members are independent, listing examples of relationships or ties that would disqualify a director from being considered independent. Investors care because a board with genuinely independent directors acts like an impartial referee overseeing management decisions, reducing conflicts of interest and improving the chance that shareholder interests are protected and corporate decisions are scrutinized effectively.

Form F-3 regulatory

"incorporated by reference into the registration statement of the Company on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-42256

WORK Medical Technology Group LTD

Floor 23, No. 2 Tonghuinan Road
Xiaoshan District, Hangzhou City, Zhejiang Province
The People’s Republic of China
+86-571-82613568
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒    Form 40-F ☐

Resignation and Appointment of Independent Director

On March 23, 2026, Mr. Xiaoyang Li, an independent director of WORK Medical Technology Group LTD (the “Company”), resigned from the board of directors (the “Board”) and as a member of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Compensation Committee of the Board, effective on the same date. Mr. Li’s resignation from the Board and the three committees was due to personal reasons.

To fill in the vacancy created by the resignation of Mr. Xiaoyang Li, on March 23, 2026, the Company extended a director offer letter to Dr. Qisheng Lin, who accepted the offer and signed a consent to act as a director of the Company. On March 23, 2026, the Board ratified and approved the appointment of Dr. Qisheng Lin to serve as an independent director of the Company, a member of each of the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, and as the chairperson of the Compensation Committee, effective as of March 23, 2026.

Dr. Lin has extensive experience in medicine and academic research. He has served as an Associate Professor in the Department of Nephrology at Renji Hospital, Shanghai Jiao Tong University School of Medicine, since January 2025, and as a Fellow in the same department since July 2024. He worked as an Associate Researcher at the Icahn School of Medicine at Mount Sinai in New York from October 2019 to January 2021. From July 2021 to June 2024, he completed his residency in the Department of Internal Medicine at Renji Hospital. Dr. Lin obtained his Ph.D. in Medicine from Shanghai Jiao Tong University School of Medicine in June 2021.

Dr. Lin does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The Board has determined that Dr. Lin is an “independent director” as defined under Nasdaq Listing Rule 5605(a)(2).

This report shall be deemed to be incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-289943) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	WORK Medical Technology Group LTD
Date: April 15, 2026	By:	/s/ Shuang Wu
	Name:	Shuang Wu
	Title:	Chief Executive Officer

2

FAQ

What board change did WORK Medical Technology Group (WOK) disclose in this 6-K?

WORK Medical Technology Group reported that independent director Xiaoyang Li resigned from the Board and three key committees on March 23, 2026. His roles included chairing the Compensation Committee, creating a vacancy the company needed to promptly fill with another independent director.

Who was appointed to replace Xiaoyang Li on the WORK Medical Technology Group (WOK) board?

The company appointed Dr. Qisheng Lin as an independent director on March 23, 2026. He also joined the Audit, Compensation, and Nominating and Corporate Governance Committees and became chairperson of the Compensation Committee, filling the responsibilities previously held by Xiaoyang Li.

Why did Xiaoyang Li resign from WORK Medical Technology Group (WOK)?

Xiaoyang Li resigned from the Board and its committees on March 23, 2026, due to personal reasons. The filing does not describe any disagreement with the company, focusing instead on the prompt appointment of a new independent director to maintain board and committee composition.

What qualifications does Dr. Qisheng Lin bring to the WORK Medical Technology Group (WOK) board?

Dr. Qisheng Lin has extensive medical and academic experience, including serving as an Associate Professor in Nephrology at Renji Hospital since January 2025. He previously held research roles at the Icahn School of Medicine at Mount Sinai and completed a residency in Internal Medicine at Renji Hospital.

Is Dr. Qisheng Lin considered independent under Nasdaq rules for WORK Medical Technology Group (WOK)?

Yes, the Board determined that Dr. Qisheng Lin is an independent director under Nasdaq Listing Rule 5605(a)(2). The filing also notes he has no family relationships with company directors or executives and no related-party transactions requiring disclosure under Regulation S-K Item 404(a).

How does this 6-K relate to WORK Medical Technology Group’s (WOK) Form F-3?

The report is deemed incorporated by reference into WORK Medical Technology Group’s Form F-3 registration statement, File No. 333-289943. This means the director and committee changes described become part of the disclosure package available to investors under that registration statement.